Prosecution Insights
Last updated: August 14, 2026

Aslan Pharmaceuticals Pte Ltd

3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready

Portfolio Summary

3
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
1
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (33%)
0
Medium (0%)
1
Easy (33%)
1
Unknown (33%)

Rejection Statute Mix

BucketCases
§101 + other1 (33%)
§112 only1 (33%)
No statute on record1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
1
Business / Other
33% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
VALENROD, YEVGENY 1 72.6% +25.1%
LOCKARD, JON MCCLELLAND 1 74.7% +27.0%
WEDDINGTON, KEVIN E 1 75.2% +10.1%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18184657 TREATMENT OF AUTOIMMUNE SKIN DISEASE WEDDINGTON, KEVIN E 182d overdue

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18184657 TREATMENT OF AUTOIMMUNE SKIN DISEASE WEDDINGTON, KEVIN E 182d overdue
18695502 METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS LOCKARD, JON MCCLELLAND 40d
18835823 DHODH INHIBITOR POLYMORPH VALENROD, YEVGENY

Top Art Units

Art UnitApps
1647 1
1629 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18835823 DHODH INHIBITOR POLYMORPH VALENROD, YEVGENY §112 Non-Final OA Pending Aug 05, 2024
18695502 METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS LOCKARD, JON MCCLELLAND 1647 Other Non-Final OA 40d Pending Mar 26, 2024
18184657 TREATMENT OF AUTOIMMUNE SKIN DISEASE WEDDINGTON, KEVIN E 1629 §101§102§103§112 Non-Final OA 182d overdue Pending Mar 16, 2023

Managing Aslan Pharmaceuticals Pte Ltd's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month